Generic Symtuza Availability

Last updated on Apr 10, 2025.

Symtuza is a brand name of cobicistat/darunavir/emtricitabine/tenofovir alafenamide, approved by the FDA in the following formulation(s):

SYMTUZA (cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate - tablet;oral)

Manufacturer: JANSSEN PRODS
Approval date: July 17, 2018
Strength(s): 150MG;800MG;200MG;EQ 10MG BASE ^[RLD]

Is there a generic version of Symtuza available?

No. There is currently no therapeutically equivalent version of Symtuza available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Symtuza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Use of solid carrier particles to improve the processability of a pharmaceutical agent
Patent 10,039,718
Issued: August 7, 2018
Inventor(s): Koziara Joanna M. & Menning Mark M. & Strickley Robert G. & Yu Richard & Kearney Brian P. & Mathias Anita A.
Assignee(s): Gilead Sciences, Inc.
The invention provides a composition comprising, a compound of formula (I):
Patent expiration dates:
- October 6, 2032
  ✓
  Drug product
Compositions and methods of treating HIV
Patent 10,786,518
Issued: September 29, 2020
Inventor(s): Boven; Katia et al.
Assignee(s): Janssen Sciences Ireland UC (Co Cork, IE); Gilead Sciences, Inc. (Foster City, CA)
The disclosure is directed to methods of treating subjects infected with HIV, once daily, with single unit dosage forms that include darunavir (or a hydrate or solvate thereof), cobicistat, emtricitabine, and a tenofovir prodrug, or salt thereof.
Patent expiration dates:
- July 19, 2038
  ✓
  Patent use: TREATMENT OF HIV-1 INFECTION IN ADULT OR PEDIATRIC PATIENTS (>=40 KG) WITH <50 COPIES/ML HIV-1 RNA AFTER >= 6 MONTHS ON PRIOR ANTIRETROVIRAL REGIMEN AND NO KNOWN DARUNAVIR OR TENOFOVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
Prodrugs of phosphonate nucleotide analogues
Patent 7,390,791
Issued: June 24, 2008
Inventor(s): Becker; Mark W. et al.
Assignee(s): Gilead Sciences, Inc. (Foster City, CA)
A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) ##STR00001## having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.
Patent expiration dates:
- April 17, 2025
  ✓
  Drug substance
  ✓
  Drug product
Pseudopolymorphic forms of a HIV protease inhibitor
Patent 7,700,645
Issued: April 20, 2010
Inventor(s): Vermeersch; Hans Wim Pieter et al.
Assignee(s): Tibotec Pharmaceuticals Ltd. (Little Island, Co. Cork, IE)
New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sul- fonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.
Patent expiration dates:
- December 26, 2026
  ✓
  Drug substance
  ✓
  Drug product
Modulators of pharmacokinetic properties of therapeutics
Patent 8,148,374
Issued: April 3, 2012
Inventor(s): Desai Manoj C. & Liu Hongtao & Xu Lianhong
Assignee(s): Gilead Sciences, Inc.
The present application provides for a compound of Formula IV,
Patent expiration dates:
- September 3, 2029
  ✓
  Patent use: TX OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENATES IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
  ✓
  Drug substance
  ✓
  Drug product
- September 3, 2029
  ✓
  Patent use: TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
  ✓
  Drug substance
  ✓
  Drug product
- September 3, 2029
  ✓
  Patent use: TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
  ✓
  Drug substance
  ✓
  Drug product
- September 3, 2029
  ✓
  Patent use: TX OF HIV1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS & PEDIATRIC PATIENTS AT LEAST 40KG HAVING NO PRIOR ARV TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MO
  ✓
  Drug substance
  ✓
  Drug product
- September 3, 2029
  ✓
  Patent use: TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG WHO HAVE NO PRIOR ARV TREATMENT HISTORY
  ✓
  Drug substance
  ✓
  Drug product
- September 3, 2029
  ✓
  Patent use: TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS
  ✓
  Drug substance
  ✓
  Drug product
Tenofovir alafenamide hemifumarate
Patent 8,754,065
Issued: June 17, 2014
Inventor(s): Liu Dazhan & Shi Bing & Wang Fang & Yu Richard Hung Chiu
Assignee(s): Gilead Sciences, Inc.
A hemifumarate form of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine (tenofovir alafenamide), and antiviral therapy using tenofovir alafenamide hemifumarate (e.g., anti-HIV and anti-HBV therapies).
Patent expiration dates:
- August 15, 2032
  ✓
  Patent use: TREATMENT OF HIV-1 INFECTION IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
  ✓
  Drug substance
  ✓
  Drug product
- August 15, 2032
  ✓
  Patent use: TREATMENT OF HIV-1 INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40 KG WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
  ✓
  Drug substance
  ✓
  Drug product
Tenofovir alafenamide hemifumarate
Patent 9,296,769
Issued: March 29, 2016
Inventor(s): Liu Dazhan & Shi Bing & Wang Fang & Yu Richard Hung Chiu
Assignee(s): Gilead Sciences, Inc.
A hemifumarate form of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine (tenofovir alafenamide), and antiviral therapy using tenofovir alafenamide hemifumarate (e.g., anti-HIV and anti-HBV therapies).
Patent expiration dates:
- August 15, 2032
  ✓
  Patent use: TREATMENT OF HIV-1 INFECTION IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
  ✓
  Drug substance
  ✓
  Drug product
- August 15, 2032
  ✓
  Patent use: TREATMENT OF HIV-1 INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40 KG WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
  ✓
  Drug substance
  ✓
  Drug product

More about Symtuza (cobicistat / darunavir / emtricitabine / tenofovir alafenamide)

Patient resources

Symtuza drug information

Professional resources

Related treatment guides

HIV Infection

Glossary

Term	Definition
Drug Patent	A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity	Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD	A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

8.3 / 10

9 Reviews

Images

Pill JG 8121 is Symtuza cobicistat 150 mg / darunavir 800 mg / emtricitabine 200 mg / tenofovir alafenamide 10 mg — Symtuza cobicistat 150 mg / darunavir 800 mg / emtricitabine 200 mg / tenofovir alafenamide 10 mg (JG 8121)